CD20 is a molecular target for scFvFc:ζ receptor redirected T cells: Implications for cellular immunotherapy of CD10+ malignancy

Biology of Blood and Marrow Transplantation

Volumn 4, Issue 2, 1998, Pages 75-83

  Jensen, Michael ^a   Tan, Giselle ^a   Forman, Stephen ^a   Wu, Anna M ^a   Raubitschek, Andrew ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Chimeric receptors; Lymphoma; Redirected T cells

Indexed keywords

CD20 ANTIGEN; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; BLOOD; CELL CULTURE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA CELL LINE; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD20; HUMANS; IMMUNOTHERAPY; JURKAT CELLS; LYMPHOMA, B-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0031610524     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.1998.v4.pm9763110     Document Type: Article

References (38)

1. Shipp MA, Mauch PM, Harris NL: Non-Hodgkin's lymphomas. In: VT DeVita, S Hellman, SA Rosenberg (eds) Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven Publishers, 2165, 1997.
2. Glass AG, Karnell LH, Menck HR: The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer 80:2311, 1997.
3. Heslop HE, Rooney CM: Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 157:217, 1997.
4. Gross G, Eshhar Z: Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J 6:3370, 1992.
5. Eshhar Z, Waks T, Gross G, Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90:720, 1993.
6. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z: Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151:6577, 1993.
7. Moritz D, Wels W, Mattern J, Groner B: Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A 91:4318, 1994.
8. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA: In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369, 1995.
9. Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL: Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 157:836, 1996.
10. Hekele A, Dall P, Moritz D, Wels W, Groner B, Herrlich P, Ponta H: Growth retardation of rumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Int J Cancer 68:232, 1996.
11. Vervoordeldonk SF, Merle PA, van Leeuwen EF, von dem B, Slaper-Cortenbach IC: Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer 73:1006, 1994.
12. Press OW, Howell-Clark J, Anderson S, Bernstein I: Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83:1390, 1994.
13. + conductance found constitutively in B lymphocytes. J Cell Biol 121:1121, 1993.
14. + T lymphocytes armed with universal T-cell receptors. Blood 84:2878, 1994.
15. Weissman AM, Baniyash M, Hou D, Samelson LE, Burgess WH, Klausner RD: Molecular cloning of the zeta chain of the T cell antigen receptor. Science 239:1018, 1988.
16. Pelloquin F, Lamelin JP, Lenoir GM: Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol 22:689, 1986.
17. Kranz DM, Tonegawa S, Eisen HN: Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 81:7922, 1984.
18. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238, 1992.
19. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995.
20. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551, 1996.
21. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schirartzentruber DJ, Aebersold P, Leitman S, Lineban WM, Seipp CA: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622, 1993. Erratum. J Natl Cancer Inst 85:1091, 1993.
22. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 319:1676, 1988.
23. van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229, 1995.
24. Porter DL, Antin JH: Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. Cancer Treat Res 77:57, 1997.
25. van Lochem E, de Gast B, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 10:181, 1992.
26. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM: Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90:549, 1997.
27. Dolstra H, Fredrix H, Preijen F, Goulmy E, Figdor CG, de Witte TM, van de Wiel-van Kemenade E: Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 158:560, 1997.
28. Dohi Y, Higasa M, Nishimura M, Hirayama A, Takagaki Y, Yamada K, Inoue K, Shinka S: Successful generation of cytotoxic T lymphocytes specific for self immunoglobulin-determinants on B lymphocytes. J Immunol 135:47, 1985.
29. Chakrabarti D, Ghosh SK: Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. III. MHC class I-restricted CTL recognizes the processed form(s) of idiotype. Cell Immunol 144:455, 1992.
30. Irving BA, Weiss A: The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64:891, 1991.
31. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M: Single-chain antigen-binding proteins. Science 242:423, 1988. Erratum. Science 244:409, 1989.
32. Gross G, Levy S, Levy R, Waks T, Eshhar Z: Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. Biochem Soc Trans 23:1079, 1995.
33. Glimcher LH, Kim KJ, Green I, Paul WE: Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J Exp Med 155:445, 1982.
34. Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, Pinkus GS, Nadler LM: Jn vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 90:4297, 1997.
35. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dörken B: Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 159:3808, 1997.
36. Chao CC, Jensen R, Dailey MO: Mechanisms of L-selectin regulation by activated T cells. J Immunol 159:1686, 1997.
37. Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES: Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci U S A 94:7509, 1997.
38. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719, 1997.